ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2026
[Research Progress on the Role and Mechanisms of PYCR1 in Tumorigenesis and Progression].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyrroline-5-carboxylate reductase 1 (PYCR1) is a key enzyme in the proline biosynthesis pathway and has garnered widespread attention in the field of tumor research in recent years. Studies have shown that PYCR1 is abnormally expressed in a variety of malignant tumors. It plays a significant role in tumorigenesis and development by participating in metabolic reprogramming of tumor cells, regulating key signaling pathways, influencing the tumor microenvironment, and mediating immune evasion, among other mechanisms. This article systematically reviews the biological structure and functions of PYCR1, its expression characteristics in various tumors, and the underlying molecular mechanisms. The focus is on exploring its role in promoting the occurrence and development of different tumors, as well as its involvement in mediating chemotherapy resistance. Additionally, the research progress and clinical application prospects of PYCR1 as a potential therapeutic target are analyzed, providing a theoretical basis and research directions for the development of novel anti-tumor strategies. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.